

Comparative Evaluation of Fixed Dose Combinations of Fluticasone/ Formoterol and Budesonide/ Formoterol in Patients of Mild- Moderate Bronchial Asthma

Kaushal S^{1*}, Singh J², Kajal NC³ and Biswas A⁴

¹Department of Pharmacology, Government Medical College, India

²Additional Professor, Department of Pharmacology, Government Medical College, India

³Department of TB & Respiratory Diseases, Government Medical College, Amritsar, India

⁴Department of Anaesthesiology and Critical Care, Fortis Hospital Mohali, India

***Corresponding author:** Shaveta Kaushal, Department of Pharmacology, Government Medical College, Amritsar, India, Tel: 8288095604; E-mail: shaveta.kb@gmail.com.

Research Article

Volume 1 Issue 2

Received Date: July 21, 2016

Published Date: August 19, 2016

Abstract

The prevalence of asthma is rising worldwide with 10–12% adults and 15% children affected presently. It can have a considerable impact on the quality of life of both, patients and their caregivers. Fixed dose combination of Inhaled corticosteroids (ICS) like fluticasone and budesonide and long acting beta 2 agonists (LABAs) in the form of metered dose inhaler (MDI) are synergistic in action and provide effective control in asthma.

Objectives: In the present study, two ICS & LABA combinations i.e. fluticasone/ formoterol and budesonide/ formoterol were compared, both administered through a metered dose inhaler (MDI) with a spacer, for achieving and maintaining asthma control, improving symptoms, pulmonary function tests and quality of life in patients of mild to moderate bronchial asthma.

Methods: It was a prospective, open- label, randomized, parallel study conducted for a total duration of 12 weeks. The parameters used to compare the two MDIs at 0, 6 and 12 weeks were:

- Pulmonary function tests – FEV₁, PEFr
- Asthma control scoring (according to the GINA definition of "control")
- Standardized Asthma Quality of Life Questionnaire [AQLQ(S)]
- Adverse effect profile

Results: By the end of 12 weeks, asthma control was similarly achieved among the two groups except that fluticasone/ formoterol was significantly better than budesonide/ formoterol in reducing the need for rescue bronchodilator use (p= 0.000) and in improving daytime symptoms at 6 weeks (p=0.000). Fluticasone/ formoterol at 6 weeks, significantly increased the percent predicted PEFr (p= 0.007) and percent improvement in AQLQ(S) score (p=0.006) in comparison to budesonide/ formoterol.

Conclusion: Fixed dose combination MDIs containing fluticasone/ formoterol and budesonide/ formoterol are effective in elevating pulmonary functions, controlling & relieving symptoms and revamping the quality of life in patients of bronchial asthma. Fluticasone/ formoterol were better in providing a more rapid and greater improvement in percent predicted PEFr, controlling daytime symptoms for a longer time and reducing the need for rescue therapy. Both the treatments were well tolerated.

Asthma is a chronic disease with recurrent episodes of breathlessness, wheeze, cough and expectoration and is defined as “chronic inflammatory disorder of airways” characterized by [1] airway obstruction that is reversible either spontaneously or with treatment; [2] airway inflammation and [3] airway hyper-responsiveness to a variety of stimuli [1]. Its prevalence is rising worldwide with 10–12% of adults and 15% of children affected presently (more than 300 million people) and it is estimated that 100 million more people may be affected by 2025 [2]. The overall prevalence in India is 2.38%. Female sex, advancing age, urban residence, lower socio-economic status, history of atopy, asthma in a first degree relative and all forms of tobacco smoking are associated with significantly higher odds of having asthma [3]. Asthma can have a considerable impact on the quality of life of patients and their caregivers. The vast economic burden comprises both direct costs, such as emergency care, hospitalizations and medications, and indirect costs, largely driven by absenteeism and reduced productivity [4,5]. It is diagnosed as reversibility of airflow obstruction in response to inhaled bronchodilator, with spirometer demonstrating a 12% improvement and 200 ml increase in forced expiratory volume in 1 second (FEV1) [6]. The efficacy of inhaled corticosteroids (ICS) in reducing airway inflammation and hyper-responsiveness has led to their widespread use as initial therapy in the treatment of patients with moderate-to-severe asthma, especially those requiring daily beta-2 adrenoceptor agonists [7]. These drugs are highly efficacious in reducing symptoms, frequency and severity of exacerbations and risk of a life-threatening attack. ICSs drastically improve lung function and asthma quality of life (AQLQ) of asthmatic patients [8-10]. An aerosolized short acting β 2-agonist (SABA) is the bronchodilator of choice as a symptom-reliever in acute, severe asthma and a long acting β 2-agonist (LABA) in combination with inhaled corticosteroid (ICS) is used as disease-controller in chronic asthma [11].

ICS and LABA in conjunction effectively achieve a higher level of asthma control and reduce exacerbations and asthma-related hospitalizations [12,13]. There is a strong rationale of combining ICS and LABA as they optimize each others' beneficial actions in the airways. Corticosteroids increase the transcription of beta-2 receptors which protects against the down-regulation of beta-2 receptors in response to long-term exposure to LABAs. LABAs potentiate the molecular mechanism of corticosteroid actions, with increased nuclear localization of glucocorticoid receptors and a synergistic suppression of inflammatory mediator release [14]. Currently accepted goal of asthma care [15] is to achieve and

maintain control of the clinical manifestations for prolonged periods so that patients can prevent most attacks, avoid troublesome symptoms day and night and keep physically active. In the present study, two ICS & LABA combinations i.e. fluticasone/ formoterol and budesonide/ formoterol were compared, both administered through a metered dose inhaler (MDI) with a spacer, for achieving and maintaining asthma control, improving symptoms, quality of life and pulmonary function tests, over 12 weeks in patients of mild to moderate bronchial asthma.

The main parameters used to compare the said combination inhalers were:

- Asthma control scoring (according to the GINA definition of "control")
- Pulmonary function tests – FEV₁, Peak expiratory flow rate (PEFR)
- Standardized Asthma Quality of Life Questionnaire [AQLQ(S)]
- Adverse effect profile

Material and Methods

Study design

It was a prospective, open-label, randomized, parallel study conducted for a total duration of 12 weeks including one baseline and two follow-up observations. The study was conducted on 80 patients of bronchial asthma attending the outpatient department (OPD) of the Tuberculosis and Respiratory Diseases Hospital attached to the Government Medical College, Amritsar after seeking the approval of the institutional thesis committee and ethics committee. Symptom score of each patient was noted at the beginning of the study and accordingly, the patients with mild to moderate symptoms were included [15].

Inclusion criteria

- Asthmatic patients aged 17- 70 yrs
- Reversibility of airway obstruction (>12% and 200 ml increase in FEV1) after 2 puffs of inhaled salbutamol – ‘Salbutamol challenge test’ [6]
- FEV1 \leq 80% of the predicted normal value when not taking short-acting bronchodilator medication for the previous 6 hours and ICS+ LABA combination 12 hours prior to screening visit [16]
- Patients not receiving inhaled steroids for previous 2 weeks and not receiving oral/ parenteral steroids for the last 4 weeks

5. Able to use metered dose inhaler (MDI) with zerostat VT spacer and perform the spirometer as per the study requirement [17]

Exclusion criteria

- a) Irreversible airway obstruction
- b) Chronic Obstructive Pulmonary Disease, Chronic bronchitis, Cor pulmonale
- c) Patients having steroid dependent asthma
- d) Tuberculosis – active or old, treated patients
- e) Ischemic heart disease
- f) Severe respiratory tract infections
- g) Contraindications to corticosteroid use, like diabetes mellitus, severe hypertension, ischemic heart disease
- h) Patients having any other illness thought to affect quality of life adversely
- i) Current or ex- smokers more than 10 pack years
- j) Pregnant and lactating mothers

Methodology

The patients were recruited after taking informed consent and randomly divided into two groups A and B.

Group A included 40 asthmatic patients who were prescribed fluticasone/ formoterol (125/ 6 microgram per puff) one puff twice daily, administered through an MDI and a spacer device.

Group B included 40 asthmatic patients who were to take budesonide/ formoterol (200/ 6 microgram per puff) one puff twice daily, administered through an MDI and a similar spacer device.

Detailed history of atopy, allergy, smoking, and number of acute exacerbations, factors triggering exacerbations, family & occupational history was taken for each patient. Quarries were made to rule out any cardiac diseases, hypertension, diabetes or any previous history of intolerance or allergy to inhaled steroids and beta agonists. Every patient was subjected to X- ray chest PA view. Asthmatic patients either had a normal X-ray or showed bronchovascular prominence or hyperinflation during an attack. Pulmonary function tests were performed in each case at start of the study, at 6 weeks and 12 weeks which included:

1. FEV1 (Forced expiratory volume in 1 second)
2. PEFr (Peak expiratory flow rate)

Percentage reversibility in FEV1 was calculated by repeating the FEV1 ten minutes after inhalation of 2 puffs

of salbutamol (100 microgram/ puff) by using the formula: $(\text{Post bronchodilation FEV1}) - (\text{Pre bronchodilation FEV1}) \times 100 / \text{Pre bronchodilation FEV1}$ These tests were done using a computerized spirometer 'Spirolab 2' [18] which also gave the predicted values of FEV1 and PEFr of each patient depending on their height, weight, age, sex and environmental temperature [19]. Levels of asthma control over 0, 6 and 12 weeks were assessed and graded into controlled, partly controlled and uncontrolled according to the criteria given by GINA 2011 [15]. Patients were also administered an interview based Standardized Asthma Quality of Life Questionnaire [AQLS (S)] at the baseline visit, 6 weeks and 12 weeks. The questionnaire was available in English, Hindi and Punjabi. For illiterate patients, questions were explained verbally and after being convinced that the patient understood the meaning of the question put to him, the response was recorded. Questions were asked in the order specified in the questionnaire. There was no advice, suggestion or encouragement from the interviewer's side to the patient. [AQLQ(S)] is a structured disease specific quality of life questionnaire developed to measure the functional (physical, social and emotional) problems that trouble the patients of asthma. It contains in total 32 items that measure four domains of health i.e. symptoms, emotional function, effect of environmental stimuli and activity limitation [20]. All responses were recorded on a scale of 1 to 7 and score of each domain was expressed as a mean of score given to each item. Overall quality of life was assessed from mean score of all domains and graded into 7 levels of severity as follows:

- i. Totally limited
- ii. Extremely limited
- iii. Very limited
- iv. Moderate limitation
- v. Some limitation
- vi. A little limitation
- vii. Not at all limited

The patients were instructed about the correct use and maintenance of metered dose inhaler (MDI) with zero stat spacer device, [21] and were advised to take care of oral hygiene. They were asked to keep a diary record of symptom severity and the frequency of rescue salbutamol puffs used. They were allowed to take as many salbutamol puffs as demanded by their symptoms along with daily dose of fluticasone/ formoterol or budesonide/ formoterol. They were asked to come for follow-up daily for first 1 week and then weekly for the next 12 weeks. On each follow-up visit, symptom history was taken, physical examination done, PEFr, FEV1 measured and [AQLS (S)] was administered. Any side effects of the drugs were

noted. Patients who deteriorated or had acute severe attacks were managed accordingly and dropped from the study. Those suffering mild exacerbations were continued to be a part of the study and the number of exacerbations was noted in each patient. At the end of the study, the entire data was compiled, tabulated and analyzed statistically using Student 't' test and Chi square test.

Results


The two treatment groups were well-matched with respect to all key **demographic characteristics** and other variables at baseline as shown in Table 1.

	Baseline Characteristics	Fluticasone/ Formoterol	Budesonide/ Formoterol	p value
1.	Number of patients	40	40	-
2.	Sex Male- n (%)	23 (57.5)	23 (57.5)	-
	Female- n (%)	17 (42.5)	17 (42.5)	-
3.	Age in years (Mean \pm SD)	40.50 \pm 14.85	37.73 \pm 15.33	0.41
4.	Duration of asthma in years (Mean \pm SD)	20.23 \pm 13.61	18.05 \pm 11.89	0.45
5.	History of atopy- n (%)	22 (55)	18 (45)	0.37
6.	Family history of asthma- n (%)	18 (45)	11 (27.5)	0.10
7.	Patients hospitalized at least once during the last year- n (%)	29 (72.5)	26 (65)	0.47
8.	No of exacerbations in the last year (Mean \pm SD)	1.40 \pm 0.71	1.45 \pm 0.85	0.78
9.	Socioeconomic status High- n (%)	5 (12.5)	2 (5)	0.36
	Average- n (%)	9 (22.5)	13 (32.5)	
	Low- n (%)	26 (65)	25 (62.5)	
10.	FEV1 at baseline (Mean \pm SD)	1.12 \pm 0.47	1.09 \pm 0.47	0.72
11.	PEFR at baseline (Mean \pm SD)	4.04 \pm 1.75	3.67 \pm 1.92	0.37

Table 1: Patient characteristics at baseline.

History revealed that an acute exacerbation of asthma was triggered by multiple factors and most patients had

exacerbations due to more than one trigger. The common factors were as shown in Figure 1.



Pulmonary function tests improved over baseline values and percent predicted values in both treatment groups during the course of the study and this change was highly

significant ($p = 0.000$). The inter-group differences in FEV1 and PEFR change from baseline was not statistically significant as depicted in table 2.

		Fluticasone/ Formoterol	Budesonide/ Formoterol	t value	p value
FEV1	At day 0	1.12 ± 0.47	1.09 ± 0.47	0.36	0.72
	At 6 weeks	1.93 ± 0.57	1.89 ± 0.57	0.32	0.75
	At 12 weeks	2.42 ± 0.65	2.48 ± 0.61	0.42	0.68
PEFR	At day 0	4.04 ± 1.75	3.67 ± 1.92	0.91	0.37
	At 6 weeks	6.47 ± 1.73	5.99 ± 1.98	1.16	0.25
	At 12 weeks	6.75 ± 1.84	6.83 ± 1.55	0.22	0.82
p values > 0.05 = Not significant					

Table 2: Inter group comparison of change in FEV1 and PEFR from baseline.

Over the 12 weeks duration, groups a (fluticasone/ formoterol) and group B (budesonide/ formoterol) were

compared with respect to 5 domains of asthma control scoring (Table 3).

Control of	Time	Fluticasone/ Formoterol (n = 40)	Budesonide/ Formoterol (n = 40)	p value
Daytime symptom	At day 0	22 (55%)	18 (45%)	0.37
	At 6 wk	40 (100%)	29 (72.5%)	0.000*
	At 12 wk	40 (100%)	40 (100%)	-
Limitation of activities	At day 0	32 (80%)	27 (67.5%)	0.20
	At 6 wk	39 (97.5%)	35 (87.5%)	0.09
	At 12 wk	39 (97.5%)	40 (100%)	0.31
Nocturnal symptoms	At day 0	16 (40%)	22 (55%)	0.18
	At 6 wk	22 (55%)	39 (97.5%)	0.000*
	At 12 wk	39 (97.5%)	40 (100%)	0.31
Need for rescue therapy	At day 0	25 (62.5%)	22 (55%)	0.49
	At 6 wk	35 (87.5%)	24 (60%)	0.005*
	At 12 wk	40 (100%)	40 (100%)	-
Lung function	At day 0	1 (2.5%)	1 (2.5%)	1.00
	At 6 wk	36 (90%)	32 (80%)	0.21
	At 12 wk	39 (97.5%)	39 (97.5%)	1.00
*p value < 0.01 = Highly significant				

Table 3: Comparison of asthma control between 2 groups.

During the treatment period, the number of additional salbutamol puffs (rescue bronchodilator) taken by the patient were noted as given in Table 4.

No. of Salbutamol puffs used	No. of patients in Fluticasone/ Formoterol group (n=40)	No. of patients in Budesonide/ Formoterol group (n=40)	Total
4	5	0	5 (6.3%)
6	23	0	23 (28.7%)
7	1	0	1 (1.3%)
8	8	4	12 (15%)
10	2	6	8 (10%)
12	1	16	17 (21.3%)

14	0	8	8 (10%)
16	0	5	5 (6.3%)
18	0	1	1 (1.3%)

Table 4: Patients using rescue bronchodilator during treatment

Mean number of salbutamol puffs used by group A (fluticasone/ formoterol) and group B (budesonide/ formoterol) was 6.53 ± 1.68 and 12.35 ± 2.43 respectively and this difference was highly significant ($p= 0.000$).

Mean AQLQ(S) scores divided into four domains (symptoms, activity limitation, emotional function and environmental stimuli) were compared between the two

groups. Both combinations i.e. fluticasone/ formoterol and budesonide/ formoterol significantly improved ($p= 0.000$) all the domain scores throughout the study period. There was no significant difference in score improvement between the two groups except for emotional function, which improved significantly in fluticasone/ formoterol group ($p=0.029$) at 6 weeks (Table 5).

DOMAINS	Time	Fluticasone/ Formoterol Mean \pm SD	Budesonide/ Formoterol Mean \pm SD	't' value	p value
Symptom score	At day 0	44.33 \pm 6.3	45.05 \pm 6.5	0.50	0.61
	At 6 wk	65.1 \pm 4.6	63.30 \pm 5.6	1.57	0.12
	At 12 wk	73 \pm 5	73.5 \pm 5.8	0.41	0.68
Activity limitation	At day 0	42 \pm 4.8	43.75 \pm 4.29	1.15	0.25
	At 6 wk	59 \pm 4.07	57.73 \pm 4.66	1.30	0.19
	At 12 wk	65.38 \pm 4.16	65 \pm 4.55	0.39	0.70
Emotional function	At day 0	20.40 \pm 2.63	21.15 \pm 2.35	1.35	0.18
	At 6 wk	27.75 \pm 1.88	26.63 \pm 2.6	2.22	0.029*
	At 12 wk	30.70 \pm 2.52	29.8 \pm 2.33	1.66	0.10
Environment al stimuli	At day 0	11.5 \pm 1.85	11.95 \pm 2.48	0.92	0.36
	At 6 wk	19.45 \pm 2.1	18.95 \pm 2.17	1.05	0.29
	At 12 wk	22.55 \pm 1.66	22.33 \pm 2.07	0.54	0.59
*p value < 0.05 = Significant					

Table 5: Inter-group comparison of mean AQLQ(S) domain scores.

Mean total AQLQ(S) score for group a (fluticasone/ formoterol) was 118 ± 12.1 at baseline that improved to 191 ± 12.29 at the end of the study. For group B (budesonide/ formoterol) this value increased from 121 ± 10.58 at baseline to 190 ± 13.15 at 12 weeks. There was no significant difference in total scores of groups A and B at any time of the study [$p= 0.08$ (6 weeks); $p= 0.73$ (12 weeks)].

Percent improvement in quality of life at 6 weeks and 12 weeks was also compared between the two groups. For group A (fluticasone/ formoterol), AQLQ(S) score increased by 45.38 ± 14.97 percent and for group B (budesonide/ formoterol), it increased by 37.16 ± 10.56 percent at 6 weeks. This difference among the two groups was statistically significant (p value < 0.05). At the end of 12 weeks quality of life increased by 62.95 ± 20.11

percent for group A and 57.02 ± 12.06 percent for group B. But this difference was not significant statistically. There was no significant difference in **adverse effect profile** between the two groups. In fluticasone/ formoterol group, 2 patients suffered from sore throat, 3 from hoarseness of voice, 1 had oropharyngeal candidiasis and 2 had upper respiratory tract infection. In budesonide/ formoterol group, 2, 1, 1 and 3 patients suffered these adverse effects respectively.

Discussion

Comparison between the two groups on the basis of improvement in pulmonary function tests (FEV1 and PEFR) demonstrated no significant change at the end of the study period as depicted in previous studies. [22,23] In concordance with past studies, fluticasone/ formoterol provided a more rapid and greater improvement in percent predicted PEFR [24,25]. Symptom control was achieved by most patients at the end of the study. Significant differences were seen at 6 weeks, when nocturnal symptoms were better controlled in budesonide/ formoterol and a higher control was seen in fluticasone/ formoterol in terms of daytime symptoms and need for rescue therapy analogous to the results of another study [26]. During the course of therapy, the average number of rescue bronchodilator puffs (salbutamol 200 mcg per puff) required by patients in fluticasone/ formoterol group was significantly lower than that for budesonide/ formoterol group. Therefore fluticasone/ formoterol was better in controlling asthma symptoms for a longer time as recorded by a double – blind, randomized, parallel study where percent days without the use of additional bronchodilator was significantly more in fluticasone/ formoterol group as compared to budesonide/ formoterol group [27]. AQLQ(S) scoring did not differ significantly between the two groups, except for the emotional function at 6 weeks, which improved more in fluticasone/ formoterol group. Also the overall percent improvement at 6 weeks was higher with fluticasone than with budesonide. In a similar study done previously, there were significant treatment differences in favor of fluticasone in three of the four domains - activity limitations, symptoms, and emotional function [28]. Both the treatments were well tolerated and there was no significant difference in incidence of side effects between them.

Conclusion

This study concludes that fixed dose combinations MDIs containing fluticasone/ formoterol and budesonide/

formoterol are very effective in elevating pulmonary functions, controlling & relieving symptoms and revamping the quality of life in patients of bronchial asthma. Fluticasone/ formoterol were better in providing a more rapid and greater improvement in percent predicted PEFR, in controlling daytime symptoms for a longer time and reducing the need for rescue therapy.

References

1. (1962) Definition and classification of chronic bronchitis, asthma & pulmonary emphysema. *Am Rev Resp Dis* 85:762-768.
2. Masoli M, Fabian D, Holt S, Beasley R (2004) Global burden of asthma, a report for the Global Initiative for Asthma. *Allergy* 59(5): 469-478.
3. Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, et al. (2006) Prevalence and Risk Factors for Bronchial Asthma in Indian Adults: A Multicentre Study. *Indian J Chest Dis Allied Sci* 48(1): 13-22.
4. Dean BB, Calimlim BM, Kindermann SL, Khandker RK, Tinkelman D (2009) The impact of uncontrolled asthma on absenteeism and health-related quality of life. *J Asthma* 46(9): 861-866.
5. Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, et al. (2009) Economic burden of asthma: a systematic review. *BMC Pulm Med* 9: 24.
6. Rust G, Westney G (1980) Pulmonary medicine. In: Hinshaw HC, Murray JF (eds) *Diseases of the chest*. 4th (ed) Philadelphia: Saunders. pp 261-98.
7. Morris HG (1985) Mechanism of glucocorticoid action in pulmonary diseases. *Chest* 88(2):133-141
8. Blais L, Suissa S, Boivin JF, Ernst P. First (1998) treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. *Thorax* 53:1025-1029
9. Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids. *New developments*. *Am J Respir Crit Care Med* 157: 51-53.
10. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, et al. (1992) Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. *Am Rev Respir Dis* 145(3): 669-674.

11. Barisione G, Baroffio M, Crimi E, Brusasco V (2010) β -adrenergic agonists. *Pharmaceuticals* 3: 1016-44.
12. Vogelmeier C, Naya I, Ekelund J (2012) Budesonide/formoterol maintenance and reliever therapy in asian patients (aged ≥ 16 years) with asthma: A sub-analysis of the COSMOS study. *Clin Drug Investig* 32(7): 439-449.
13. Woolcock A, Lundback B, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med* 153(5): 1481-1488.
14. Barnes PJ (2002) Scientific rationale for inhaled combination therapy with long-acting β_2 -agonists and corticosteroids. *Eur Respir J* 19(1): 182-191.
15. (2011) Global initiative for asthma. Global strategy for asthma management and prevention.
16. Urso DL, Daniele V, Formaro L, Urso G (2012) Diagnosis and treatment of asthma. *Recenti Prog Med* 103(7-8): 284-287.
17. American Thoracic Society (1991) Lung functions testing: selection of reference values and interpretive strategies. *Am Rev Respir Dis* 144 (5):1202-1218
18. Perillo M, Spirolab II (2001) User's Manual Rev 2. Medical international research.
19. Kamat SR, Sarma BS, Raju VR, Venkataraman C, Balkrishna, et al. (1977) Indian norms for pulmonary function: observed values prediction equations and inter correlations. *J Assoc Physicians India* 25(8): 531-540.
20. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR (1999) Validation of a standardized version of the asthma quality of life questionnaire. *Chest* 115(5): 1265-1270.
21. Press VG, Arora VM, Shah LM, Lewis SL, Charbeneau J, et al. (2012) Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: a randomized trial. *J Gen Intern Med* 27(10): 1317-1325.
22. Gogtay JA, Balki A, Dalal S, Singh A, Bardapurkar S, et al. (2010) Efficacy and tolerability of a new HFA-Propelled fluticasone/formoterol combination inhaler compared to budesonide/formoterol combination in subjects with moderate to persistent asthma. *Chest* 138(4): 161.
23. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R (1999) Systemic Effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. *Am j respir crit care med* 160(1): 157-161.
24. Ayres JG, Bateman ED, Lundbäck B, Harris TAJ (1995) High dose fluticasone propionate, 1 mg daily versus fluticasone propionate, 2 mg daily or budesonide, 1.6 mg daily in patients with chronic severe asthma. *Eur Respir J* 8(4): 579-586.
25. Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, et al. (1996) Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 mcg per day. *Eur Respir J* 9(11): 2263-2272.
26. Adams NP, Lasserson TJ, Cates CJ, Jones P (2007) Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. *Cochrane Database Syst Rev* 17(4): CD002310.
27. Ringdal N, Swinburn P, Backman R, Plaschke P, Sips AP, et al. (1996) A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation. *Mediators of Inflammation* 5(5): 382-389.
28. Rutherford C, Mills R, Gibson PG, Price MJ (2003) Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. *Respirology* Sept 8(3): 371-375.